We also assessed 481 patients with NSCLC (192 [40.0%] with MUC16 variant) who did not receive ICI therapy and found no difference in OS between MUC16 variant and wild-type tumors (HR, 0.94; 95% CI, 0.71-1.25; P = .66). The gene discussed is MUC16; the disease is non-small cell lung carcinoma.